Skip to main
  1. Stocks
  2. Abbott Labs
  3. Forecast
ABT

Abbott Labs (ABT) Stock Forecast & Price Target

Abbott Labs (ABT) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 48%
Buy 52%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Abbott Laboratories is favored because its near-term reset appears driven by temporary electrophysiology and diabetes headwinds rather than a break in the long-term growth thesis, while Nutrition, Diagnostics, and core device franchises continue to post resilient results. The company reported Nutrition revenue of about $2.3 billion in 3Q26, Diagnostics sales of roughly $1.6 billion, and EP growth of 10% in Rhythm Management and double-digit gains in ablation ex-LAA, underscoring broad-based operational strength. Management also expects the Nutrition separation by year-end 2027 to sharpen the portfolio and lift sales growth by 50-100 bps, gross margin by more than 200 bps, and operating margin by about 100 bps, while multiple product catalysts support 2027 acceleration.

Bears say

Abbott Laboratories is facing a negative outlook because its core businesses are exposed to persistent pricing pressure in Nutrition and Medical Devices, along with regulatory timing risk, competitive threats, and uncertainty around demand across emerging-market pharmaceutical launches. The company also faces share loss and slower growth in key franchises, as highlighted by competition in MitraClip, Libre, and Amulet versus entrenched rivals, while FX, inflation, supply-chain disruptions, and weaker-than-expected Covid-19 testing could further pressure results. Even with a 2026 revised forecast of $49.994B in revenue and $5.52 in adjusted EPS, the model still implies only mid-single-digit revenue growth and high-single-digit EPS growth, underscoring limited upside against these headwinds.

Abbott Labs (ABT) has been analyzed by 21 analysts, with a consensus rating of Buy. 48% of analysts recommend a Strong Buy, 52% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abbott Labs and is not a guaranteed prediction by Public.com or investment advice.

Abbott Labs (ABT) Analyst Forecast & Price Prediction

Get the latest Abbott Labs (ABT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Abbott Labs (ABT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abbott Labs (ABT) Forecast

Analysts have given Abbott Labs (ABT) a Buy based on their latest research and market trends.

According to 21 analysts, Abbott Labs (ABT) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $121.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $121.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abbott Labs (ABT)


Abbott Labs (ABT) Analyst Forecast & Price Prediction

Get the latest Abbott Labs (ABT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Abbott Labs (ABT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ABT stock data and trends